Myeloproliferative Neoplastic Diseases Observatory From Brest
Launched by UNIVERSITY HOSPITAL, BREST · Sep 7, 2016
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called the Myeloproliferative Neoplastic Diseases Observatory from Brest, is studying three specific blood disorders: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The aim is to gather information from patients who are diagnosed or being treated for these conditions at Brest University Hospital. It’s important to note that this is an observational study, meaning that researchers will not be providing any treatment; instead, they will simply be following the health of the patients over time.
Eligible participants are those diagnosed with one of the three conditions mentioned and who agree to take part by signing a consent form. There are no specific exclusions, so anyone meeting the criteria can participate. Throughout the study, patients will be monitored until there are important updates about their health or treatment, such as a change in their care or if they pass away. This study aims to improve understanding of these blood disorders and how they affect patients over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with essentiel thrombocythemia, polycythemia vera or primary myelofibrosis
- • Signature of the non-opposition consent form
- Exclusion Criteria:
- • None
About University Hospital, Brest
The University Hospital of Brest is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. With a strong emphasis on interdisciplinary collaboration, the hospital serves as a hub for cutting-edge clinical trials aimed at improving treatment outcomes across various medical specialties. Leveraging its robust academic affiliations and state-of-the-art facilities, the University Hospital of Brest is committed to fostering scientific discovery and enhancing the quality of life for patients through evidence-based practices and pioneering research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brest, , France
Patients applied
Trial Officials
Jean-Christophe Ianotto
Study Director
CHRU de Brest
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials